ScreenerHero

EGTX Egetis Therapeutics AB (publ)

STO · SE · Healthcare · Biotechnology · egetis.com
9.060SEK-1.31%Mkt Cap: 402.94M $P/E: —

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap402.94M USD
Enterprise Value378.65M USD
Revenue (TTM)6.31M USD
Gross Profit1.19M USD
Net Income (TTM)-32.76M USD
Revenue/Share0.17 SEK
Last Price9.060 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees56
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)76.50
PEG—
EV/EBITDA-10.39
EV/Revenue59.98
P/S64.67
P/B8.86
EPS (TTM)-1.00
EPS (Forward)0.12
52W Range
3.62590% of range9.680
52W High9.680 SEK
52W Low3.625 SEK
Profitability
Gross Margin19.87%
Oper. Margin-627.59%
EBITDA Margin0.00%
Profit Margin-548.88%
ROE-101.15%
ROA-53.59%
Growth
Revenue Growth20.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.54M USD
CapEx (TTM)143.48K USD
FCF Margin-225.45%
FCF Yield-3.53%
Net Debt-29.61M USD
Net Debt/EBITDA0.81
Balance Sheet
Debt/Equity0.27
Current Ratio1.49
Quick Ratio1.46
Book Value/Sh1.04 SEK
Cash/Share0.81 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.32 SEK
Upside (mean)+102.3%
Target Range4.300 SEK – 33.00 SEK
4.300+102.3% to mean33.00
# Analysts4
Ownership
Shares Out.464.97M
Float240.07M
Insiders23.39%
Institutions51.69%
Technical
SMA 507.511 (+20.6%)
SMA 2006.021 (+50.5%)
Beta0.81
S&P 52W Chg14.58%
Avg Vol (30d)2.30M
Avg Vol (10d)6.36M
Technical Indicators
RSI (14)67.3
MACD0.3724
MACD Signal0.2519
MACD Hist.+0.1205
BB Upper9.110 SEK
BB Middle8.076 SEK
BB Lower7.043 SEK
BB Width25.60%
ATR (14)0.4792 SEK
Vol Ratio (20d)2.30x